{"description":"Documents matching '\"right to try\"' and published on or after 04/18/2026","count":2,"total_pages":1,"results":[{"title":"Accelerating Medical Treatments for Serious Mental Illness","type":"Presidential Document","abstract":null,"document_number":"2026-07907","html_url":"https://www.federalregister.gov/documents/2026/04/22/2026-07907/accelerating-medical-treatments-for-serious-mental-illness","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-22/pdf/2026-07907.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-07907.pdf?1776784506","publication_date":"2026-04-22","agencies":[{"raw_name":"EXECUTIVE OFFICE OF THE PRESIDENT","name":"Executive Office of the President","id":538,"url":"https://www.federalregister.gov/agencies/executive-office-of-the-president","json_url":"https://www.federalregister.gov/api/v1/agencies/538","parent_id":null,"slug":"executive-office-of-the-president"}],"excerpts":"2 \n . \n FDA Review Prioritization and <span class=\"match\">Right to Try</span>. \n (a) The Commissioner of Food and Drugs shall provide Commissioner's National Priority Vouchers to appropriate psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program.\n \n (b) The FDA and Drug Enforcement Administration shall facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the <span class=\"match\">Right to Try</span> Act (21 U.S.C. 360bbb-0a), including any"},{"title":"Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.","document_number":"2026-16715","html_url":"https://www.federalregister.gov/documents/2026/08/17/2026-16715/agency-information-collection-activities-proposed-collection-comment-request-investigational-new","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-17/pdf/2026-16715.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-16715.pdf?1786711513","publication_date":"2026-08-17","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"300.200 requires the submission of an annual report by sponsors and manufacturers who provide an “\n eligible investigational drug” \n under the <span class=\"match\">Right to Try</span> Act. The regulation also establishes content and format elements and requires that information be submitted to FDA no later than March 31 of each year, including data for the preceding calendar year. Respondents use Form FDA 5023 entitled “\n <span class=\"match\">Right to Try</span> Reporting Requirement: Annual Summary,” \n currently available for download from our website at \n https://www.fda.gov/patients/learn-about-exp"}]}